Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

As Time Ticks, Industry Edges Closer To The Big Patent Cliff

Oct 04 2023

• By Jessica Merrill and Edwin Elmhirst

Clock — • Source: Shutterstock

Related Content

Despite Pfizer/Seagen’s Splash, Deals Are Staying Small

Jul 31 2023

Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Mar 13 2023

IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations

Mar 03 2023

Seagen, With Two Big Pharma Bidders, Nearly Lost Both

Apr 17 2023

Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy

Apr 17 2023

Amgen’s FTC Settlement To Allow $27.8bn Horizon Deal Closure Sets New M&A Precedent

Sep 01 2023

J&J Predicts No Stelara Biosimilar Until 2025

Jul 20 2023

The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall

Apr 04 2022

Pfizer Lays Out A Growth Plan To Offset $17bn In Coming Exclusivity Losses

Dec 13 2022

Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover

Dec 12 2022

Related Companies

Bristol Myers Squibb Company

Pfizer Inc.

Johnson & Johnson

Amgen, Inc.

Novartis AG

Merck & Co., Inc.

Novo Nordisk A/S

Eli Lilly and Company

Seagen Inc.

Horizon Therapeutics plc

Additional Topics

Business Strategies Commercial Intellectual Property Market Intelligence Strategy Sustainability Evaluate Data BioPharmaceutical

More from Business Strategy

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window